Results 91 to 100 of about 1,341 (168)

Real-World Experience With Teprotumumab in Patients With Dysthyroid Optic Neuropathy

Background: Teprotumumab, an insulin-like growth factor I receptor inhibitory antibody, improved proptosis, diplopia, inflammatory signs/symptoms, and quality of life in patients with active thyroid eye disease (TED) in clinical trials.
Madhura A. Tamhankar; Tejus Pradeep; Yuanyuan Chen; César A. Briceño
core  

Teprotumumab Treatment for Thyroid Eye Disease in a Patient with Pre-Existing Hearing Loss: Worth the Risk?

Thyroid eye disease (TED) can lead to reduced vision from corneal scarring or optic nerve compression. Other manifestations of thyroid eye disease that can be troubling for TED patients include ...
Cheryl Polinsky, Lisa Schifanella, Wyatt Hyke   +2 more
core   +1 more source

Supplementary Material for: Severe Hyperglycemia with Teprotumumab for Treatment of Thyroid Eye Disease

Introduction: Thyroid eye disease (TED) is a rare condition involving autoimmune-mediated inflammation of the orbit and periocular structures, which can result in many debilitating symptoms.
Barrientez B. (18001288), Cottom S. (18001285), Melson A. (18001291)   +2 more
core   +1 more source

A case of pretibial myxedema treated with teprotumumab

JAAD Case Reports, 2021
Lauren Petit, MD, Anna Catinis, BA, Emily Richard, MD, Joel Silverberg, MD   +3 more
doaj   +1 more source

From orbit to cortex: recognising teprotumumab-induced encephalopathy.

Autoimmune-related adverse effects may occur from monoclonal antibody medications though autoimmune encephalopathy is not a commonly reported reaction.
Siddiqui, Zuhair, DO, Tang, Connie G, MD, Spicer, Alan R, Punati, Ramya, MD, Yang, Ping-Hao, MD   +4 more
core  

Thyroid eye disease with teprotumumab-related hyperglycemia associated with increased growth hormone secretion. [PDF]

JCEM Case Rep
Sugawa K, Hataya Y, Murabe K, Fujimoto K, Iwakura T, Matsuoka N.   +5 more
europepmc   +1 more source

Testosterone Dysregulation and Erectile Dysfunction Associated With Teprotumumab Infusions: A Case Report

: This case report describes a 52-year-old male who developed testosterone dysregulation and erectile dysfunction while receiving teprotumumab infusions. He presented with active thyroid eye disease with proptosis, orbital pain, and edema.
Sri Meghana Konda, Lisa Y. Lin, Suzanne K. Freitag   +2 more
core   +1 more source

Case Report: Teprotumumab treatment in an HIV-infected patient with refractory thyroid eye disease: clinical and quantitative MRI evidence. [PDF]

Front Immunol
Zheng M, Cao J, Zhang F, Xiong W.
europepmc   +1 more source

Head-to-Head Comparison of an IGF-1R Inhibitor Versus Intravenous Glucocorticoid for Active Thyroid Eye Disease: Design of a Randomized Clinical Trial. [PDF]

Ophthalmol Ther
Zhang H, Sun J, Li Y, Huang Y, Zhang S, Zhong S, Deng J, Zhu B, Lu S, Zhang W, Han-Zhang H, Jin Y, Qian L, Zhou H, Fan X.   +14 more
europepmc   +1 more source

Correlation of Objective Ocular Alignment and Subjective Diplopia After Teprotumumab in Patients With Thyroid Eye Disease (TED)

Teprotumumab, an insulin-like growth factor one (IGF-1) antagonist improved proptosis and diplopia in patients with thyroid eye disease (TED). Prior clinical trials documented subjective improvement in diplopia in study subjects who received teprotumumab,
Tejus Pradeep; Taylor Linaburg; Cory Shoshany; Clare Teng; Kevin Zhang; Yuanyuan Chen; Cesar Briceno; Madhura Tamhankar
core